Apoptosis inducer46 is an apoptosis (apoptosis) inducer that exhibits potent and selective growth inhibitory effects on metastatic triple-negative breast cancer (TNBC) cells. It induces G2/M phase cell cycle arrest and apoptosis (apoptosis) cell death in MDA-MB-231 cells and blocks the nuclear translocation of NF-κB. Apoptosis inducer46 is useful for TNBC research.

Apoptosis inducer 46 (Compound 5d) demonstrates potent growth inhibitory effects on metastatic triple-negative breast cancer (TNBC) cells, including MDA-MB-231, HCC 1806, MCF-7, and BEAS 2B cells, with IC 50 values of 0.38 μM, 0.31 μM, 0.39 μM, and 0.7 μM, respectively. Furthermore, at concentrations of 5-40 μM over 2-4 hours, it significantly reduces proteasome activity in MDA-MB-231 cells, with an IC 50 of 37.0 μM for proteasome inhibition, and leads to the accumulation of ubiquitinated proteins. At 5 μM across 24-72 hours, the compound elevates apoptosis rates and causes cell cycle arrest at the G2/M phase in MDA-MB-231 cells. Additionally, concentrations of 5-20 μM stabilize cyclin D1, p53, and p21 proteins, prevent the degradation of IκBα, IκBε, and IκKγ, and inhibit the nuclear translocation of NF-κB in MDA-MB-231 cells.